Home › Companies › EYPT

EyePoint, Inc.

EYPT Lead: Phase 3 2 Biotech Distilled articles ↓

Ophthalmology Small Molecule

Most recent annual filing: 2026-03-05

Pipeline (3 active programs)

DURAVYU

vorolanib · EYP-1901

Small Molecule Target: VEGF receptors, PDGF, JAK1, IL-6, VEGF, PDGF receptor, IL-6/JAK1

Wet Age-Related Macular Degeneration Phase 3 intravitreal
Diabetic Macular Edema Phase 3 intravitreal

razuprotafib

EYP-2301

Small Molecule Target: TIE-2, VE-PTP

Undisclosed indication Preclinical

Technology platforms

Durasert E

Bioerodible formulation of the Durasert sustained intraocular drug delivery technology; solid drug cylinder delivered via intravitreal injection; designed for sustained release of small molecules for serious retinal diseases including wet AMD and DME

Biotech Distilled coverage (2)

2026-05-07 UPDATE: EyePoint (EYPT) — Q1 2026 Status Check Into the LUGANO Window 🔒 Paid
2026-05-01 EyePoint Pharmaceuticals (EYPT) - Scientific Deep Dive for DURAVYU and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.